However, in patients with NIU receiving TNF-α inhibitors, there are no established guidelines and there is no expert consensus on the role of TDM or on the optimal timing for measuring serum levels of ADA and AAAs, although some studies suggest that it may be beneficial. Here, ADA is linked to achalasia-alacrima syndrome.